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INTRODUCTION
Tuberous sclerosis complex (TSC) is a dominantly inherited disease
with high penetrance and morbidity, and is caused by mutations
in either TSC1 or TSC2. TSC mostly affects children, who develop
widespread lesions, known as hamartomas, in different organs,
including the central nervous system (CNS). Hamartomas, which
are considered the hallmark of the disease, comprise non-malignant
cells that exhibit abnormal cell proliferation, aberrant cell
differentiation and altered migratory ability. Typical CNS
hamartomas include cortical tubers (CTs) – which are responsible
for causing disabling neurological clinical features, such as infantile
spasms (IS), epilepsy, mental retardation (MR) and autism – as well
as asymptomatic subependymal nodules (SENs). The latter, through
the evolution into subependymal giant cell astrocytomas (SEGAs),
result in significant morbidity and mortality (Crino et al., 2006).
The existence of a significant genotype-phenotype correlation
in individuals with TSC is still a matter of debate. Most individuals
with TSC2 mutations display a more severe neurological phenotype
than those with mutations in TSC1 (Dabora et al., 2001; Devlin et
al., 2006; Jansen et al., 2008). However, only IS and epilepsy are
strongly associated with TSC2 mutations, whereas MR and
neurocognitive impairment are linked to different types and
location of TSC1 and TSC2 germline mutations, rather than to the
specific gene in which the mutation occurred (van Eeghen et al.,
2013). Similarly, the presence of SENs and SEGAs is not significantly
associated with either gene mutation (Michelozzi et al., 2013), and
variability in TSC symptoms has been reported in individuals with
identical TSC mutations (Rok et al., 2005).
To reproduce experimentally TSC, different CNS-restricted
conditional knockout murine models have been generated, by
causing loss of either Tsc1 or Tsc2 in differentiating or differentiated
neuronal cells (Tsc1c/c/Syn-Cre+ and Tsc1c/c/CaMKII-Cre+ mice)
(Meikle et al., 2007; Ehninger et al., 2008) or in differentiated
astrocytes [Tsc1c/c/hGFAP2.2kb (also known as Tsc1c/c/hGFAP1-
Cre+) and Tsc2c/c/hGFAP2.2kb (also known as Tsc2c/c/hGFAP1-
Cre+) mice] (Uhlmann et al., 2002a; Zeng et al., 2011). Given that
CTs, SENs and SEGAs are believed to originate from a neural stem
cell (NSC) undergoing abnormal differentiation, NSC-targeted
mouse models of TSC have also been recently produced by deleting:
(1) Tsc2 in embryonic radial glial cells (RGCs) (Tsc2c/–/hGFAP2-
Cre+ mice) at embryonic day 13.5 (E13.5) (Way et al., 2009), (2)
Tsc1 in Emx1-expressing embryonic dorsal telencephalic
neuroepithelial progenitors (NEPs) at E9.5 (Magri et al., 2011;
Carson et al., 2012), (3) Tsc1 in embryonic E16.5 progenitors
(Feliciano et al., 2011) and (4) Tsc1 in postnatal SVZ NSCs (Zhou
et al., 2011; Feliciano et al., 2012). Deletion of Tsc1 or Tsc2 at
different developmental stages results in a gradient of phenotypes,
with the most severe phenotypes being associated with mutations
in early embryonic neural progenitors. As such, these same CNS-
restricted TSC mouse models could be exploited to highlight
potential genotype-phenotype correlations in TSC. As an example,
conditional mice with Tsc2 gene inactivation in differentiated
astrocytes have been shown to display a more severe phenotype
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SUMMARY
Tuberous sclerosis complex (TSC) is a dominantly inherited disease with high penetrance and morbidity, and is caused by mutations in either of
two genes, TSC1 or TSC2. Most affected individuals display severe neurological manifestations – such as intractable epilepsy, mental retardation and
autism – that are intimately associated with peculiar CNS lesions known as cortical tubers (CTs). The existence of a significant genotype-phenotype
correlation in individuals bearing mutations in either TSC1 or TSC2 is highly controversial. Similar to observations in humans, mouse modeling has
suggested that a more severe phenotype is associated with mutation in Tsc2 rather than in Tsc1. However, in these mutant mice, deletion of either
gene was achieved in differentiated astrocytes. Here, we report that loss of Tsc1 expression in undifferentiated radial glia cells (RGCs) early during
development yields the same phenotype detected upon deletion of Tsc2 in the same cells. Indeed, the same aberrations in cortical cytoarchitecture,
hippocampal disturbances and spontaneous epilepsy that have been detected in RGC-targeted Tsc2 mutants were observed in RGC-targeted Tsc1
mutant mice. Remarkably, thorough characterization of RGC-targeted Tsc1 mutants also highlighted subventricular zone (SVZ) disturbances as well
as STAT3-dependent and -independent developmental-stage-specific defects in the differentiation potential of ex-vivo-derived embryonic and
postnatal neural stem cells (NSCs). As such, deletion of either Tsc1 or Tsc2 induces mostly overlapping phenotypic neuropathological features when
performed early during neurogenesis, thus suggesting that the timing of mTOR activation is a key event in proper neural development.
Timing of mTOR activation affects tuberous sclerosis
complex neuropathology in mouse models
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than those with Tsc1 deletion (Zeng et al., 2011). Conversely, genetic
inactivation of Tsc1 and Tsc2 in early embryonic neural progenitors
such as NEPs (Magri et al., 2011) and RGCs (Way et al., 2009),
respectively, resulted in very similar neocortical and hippocampal
alterations, lamination defects, generation of enlarged cells, cell
heterotopias, and epilepsy. Thus, as opposed to observations in
differentiated astrocyte-targeted Tsc1 or Tsc2 mouse models,
deletion of either Tsc1 or Tsc2 in distinct embryonic
undifferentiated neural progenitors seems to result in overlapping
phenotypes.
Because the undifferentiated progenitors NEPs and RGCs are in
any case very different molecularly and functionally, to rigorously
assess whether the phenotypes observed in Tsc1 or Tsc2 CNS-
targeted mouse models depend on the distinct nature of the cells
targeted by mutation (i.e. differentiated astrocytes versus early
undifferentiated progenitors such as NEPs and RGCs), we decided
to compare the effect of Tsc1 loss in the very same progenitor cell
type in which Tsc2 deletion was previously performed, i.e. RGCs.
RESULTS
Targeted inactivation of Tsc1 in RGCs causes shortened lifespan,
megalencephaly, cortical alteration and spontaneous epilepsy
To explore the effect of Tsc1 loss in RGCs, we interbred either
Tsc1c/c or Tsc1c/– mice with hGFAP2-Cre mice, in which Cre-
mediated recombination takes place in the hippocampal and
cortical radial glia at E12 and at E13.5-E14, respectively (Zhuo et
al., 2001). Both mutant mice were born in Mendelian ratios, and
were indistinguishable from controls until postnatal day 10 (P10).
Mutant brains at P15 were larger than in controls, mostly due to
increased cortical thickness, and showed dilated lateral ventricles
(Fig. 1A,B). Eventually, mutant mice died at 3 weeks of age (Fig. 1C).
Starting at P14, mutant mice showed a progressive decline in
activity, acquired a humped posture and all developed spontaneous
epileptic-like seizures. Video electroencephalographic (EEG)
monitoring sessions beginning at P12 revealed that background
activity was composed of sequences of oscillations of 1-4 Hz or 6-
9 Hz (n=5 mice recorded; Fig.  1D, section 1a), which were also
evident in density spectral array (DSA) plots (Fig. 1D, section 1b).
In mutants, epileptic abnormalities were often superimposed on
the background activity (Fig.  1D, section 2), especially after a
seizure; a large spike frequently appeared just before or at the
beginning of a seizure, without any behavioral correlate. High-
amplitude sharp waves characterized seizure onset, followed by
low-amplitude/high-frequency activity that progressively increased
in amplitude and decreased in frequency. This trend evolved into
a series of spike and wave complexes, ending with a marked
decrease of EEG amplitude (Fig.  1D, section 3). Seizure length
varied from 10 to 360 seconds, with a mean duration of 128±78
seconds. The mean frequency of seizures per hour was 0.14, with
an average number of 3.5 seizures per day (supplementary material
Table S1). Behaviorally, seizures started with head and truncus
rhythmical jerks, followed by fore- and hind-limb myoclonic jerks.
The Straub tail sign was also observed. Seizures ended with sudden
immobility and progressive recovery of normal behavior. In some
cases, animals died immediately after seizures.
Mutant mice in the present study did not show any overt sign
of massive weight loss or cachexia, which, by contrast, has been
observed in Tsc1c/–/Emx1-Cre+ mutant mice and contributed to
their shortened lifespan (Magri et al., 2011). Indeed, hyperactivation
of the mTOR pathway in selected hypothalamic nuclei that regulate
food intake was observed in Tsc1c/–/Emx1-Cre+ mice, possibly due
to leaky Cre activation. By contrast, although increased
phosphorylation of ribosomal protein S6 at serine 235/236
(pS6S235/6) was observed in the hypothalamus of our mutant 
Tsc1c/–/hGFAP2-Cre+ mice, this was not ectopic and was retrieved
in the same nuclei as in controls (supplementary material Fig. S1).
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TRANSLATIONAL IMPACT
Clinical issue
Tuberous sclerosis complex (TSC) is a rare, dominantly inherited disorder
associated with high penetrance and high morbidity. The disease, which is
characterized by non-malignant tumor (hamartoma) development in multiple
organs and severe neurological manifestations, is caused by mutations in
either of two tumor suppressor genes, TSC1 or TSC2. The existence of a
significant genotype-phenotype correlation in individuals bearing mutations
in TSC1 or TSC2 is a matter of debate. However, individuals with TSC2
mutations have been shown to generally display a more severe neurological
phenotype than those with mutations in TSC1. In agreement with this,
knockout mouse models have provided evidence that a more severe
neurological phenotype is associated with mutations in Tsc2 rather than in
Tsc1. In these earlier comparative studies, which implicate activation of the
mTOR pathway as a contributory mechanism, genetic inactivation of Tsc1 or
Tsc2 was limited to differentiated astrocytes. It has recently been shown that
Tsc2 loss in undifferentiated radial glial cells (RGCs; a type of neural stem cell)
also recapitulates several neurological alterations associated with TSC. A
similar investigation of the effect of Tsc1 inactivation in undifferentiated RGCs
on the mTOR pathway and TSC phenotypes has not been performed.
Results
In the present study, the authors address this issue by inducing Tsc1 loss in
undifferentiated RGCs, in vivo and in vitro. First, they generated and
characterized in-depth a novel Cre-based conditional mouse model for
targeted knockout of Tsc1. They report that deletion of Tsc1 in hippocampal
and cortical RGCs during early development results in neurological features
that are reminiscent of TSC, some of which were detected in the
corresponding Tsc2 mutant mouse that was examined previously. Using this
Tsc1 conditional knockout mouse model, the group established long-term
expanding postnatal NSC lines derived from the subventricular zone. In line
with previous observations in other types of Tsc1-deficient NSC lines, mutant
postnatal NSCs showed a robust decrease in self-renewal ability and defects in
differentiation, which were ascribed to STAT3 hyperactivation. Importantly,
inhibition of STAT3 rescued some of the differentiation defects observed in
vitro, confirming the pivotal role of this pathway, downstream of mTOR
activation, in regulating neurogenesis.
Implications and future directions
These results suggest that, contrary to earlier findings, loss of Tsc1 results in
neurological manifestations of TSC that are equivalent to those induced by
loss of Tsc2 in mutant mice. Moreover, mTOR activation was confirmed to play
a crucial role in mediating the neurological abnormalities observed. The key
difference between this work and earlier studies is that gene loss was assessed
in NSCs rather than in differentiated cells. The data indicate that mTOR
activation in neural cells can have different effects depending on the
developmental stage at which it takes place, i.e. in immature or mature cells,
and that genotype-phenotype correlation, at least in pre-clinical mouse
models, might depend on the nature of the cells targeted by the mutation.
Furthermore, the availability of developmental stage-specific NSCs provides a
tool for testing different therapeutic approaches, as exemplified by STAT3
inhibition, for their effectiveness in rescuing the defects in neural stem cell
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As such, the short lifespan of Tsc1c/–/hGFAP2-Cre+ mutant mice
was probably a consequence of the onset of status epilepticus, rather
than of cachexia and wasting.
Loss of Tsc1 in RGCs results in cortical alteration, enlarged cells,
lamination defects, perturbed myelination and restricted mTORC1
activation in neurons
Similar to Tsc2c/–/hGFAP2-Cre+ mice (Way et al., 2009),
Tsc1c/–/hGFAP2-Cre+ P15 mutant brain showed clear signs of
megalencephaly, lamination defects and microscopic cellular
alterations (n=5 mice; Fig. 2A). Enhanced mTORC1 activation,
as measured by pS6S235/6 hyperphosphorylation, and
disorganization of NeuN-immunoreactive (IR) Nissl-positive
neurons were observed in most layers of the cerebral cortex. In
fact, an ectopic layer of NeuN-IR neurons was evident between
layer VI and the corpus callosum (CC), and was uniquely
characterized by increased cell soma size (Fig. 2B). Whereas most
NeuN-IR cells in the Tsc1c/–/hGFAP2-Cre+ cortex activated pS6,
GFAP-IR astrocytes, whose overall numbers were increased, did
not (Fig. 2A). No differences in microglia activation were retrieved
(supplementary material Fig. S1). Interestingly, SMI311-IR
pyramidal neurons in layer V showed abnormal projections and
disarranged neurites and axons. Notably, STAT3, which was
previously identified as a crucial mediator of the premature
differentiation occurring in Tsc1c/–/Emx1-Cre+ NSCs, was also
hyperactivated in cells scattered through the Tsc1c/–/hGFAP2-
Cre+ cortex in vivo (pSTAT3Y705, Fig.  2A, and pSTAT3S727, not
shown).
In P15 mutant cortex, loss of Tsc1 and concurrent reduction in
Tsc2 protein, which is in line with TSC2 dependence on TSC1
expression for stabilization of the TSC1-TSC2 complex (Benvenuto
et al., 2000), led to a marked increase in pS6S235/6 (Fig. 2C). Of note,
pAKTS473 was strongly reduced, possibly due to the activation of
an IRS1-dependent negative feedback and/or the loss of mTORC2
activity. However, differences in the activation of mTORC2, as
measured by the downstream mediators pmTORS2481 and
pPKCαS643, were not detected (Fig.  2C). As opposed to
Tsc1c/–/Emx1-Cre+ mutant cortex, no significant hyperactivation
of pERK was retrieved in the Tsc1c/–/hGFAP2-Cre+ P15 cortex. In
line with immunohistochemistry (IHC) findings, pSTAT3S727 was
significantly overactivated in the Tsc1c/–/hGFAP2-Cre+ P15 mutant
cortex. No difference in the expression of Pten was observed
(Fig. 2C).
As in Tsc2c/–/hGFAP2-Cre+ mice, severe hypomyelination was
observed in Tsc1 mutants, as shown by a significant decrease in
MBP- and CNPase-IR fibers (e.g. 0% and 43.9±4.3% MBP-negative
hypomyelinated area/total area of the CC, in control and mutant
brains, respectively; Student’s t-test, P<0.002) as well as in the
number of Olig2-IR cells (39±7.0 and 15±7.0 cells/field in the CC
in control and mutant brains, respectively; Student’s t-test,
P<0.0001) (Fig. 2D).
Of note, loss of Tsc1 in RGCs resulted in the same hippocampal
enlargement and lamination alterations that were also evident in
Tsc2c/–/hGFAP2-Cre+ brain (Way et al., 2009) (supplementary
material Fig. S2). Specifically, the cornu ammonis (CA) 1 and 3
regions and the dentate gyrus (DG) of the mutant hippocampus
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Fig. 1. Hyperactivation of the mTOR pathway in
RGCs by conditional mutagenesis severely
impairs CNS development and causes early
lethality. (A)H&E staining shows that the brains 
of Tsc1c/–/hGFAP2-Cre+ mutant mice are
megalencephalic and characterized by increased
cortical thickness as compared with control mice.
Magnification 40× (upper panel), 100× (lower
panel). (B)Quantification of the increase in cortical
thickness. ***P<0.005. (C)Kaplan-Meier survival
curve indicates that mutant mice have a shortened
lifespan (n=12). Log-rank test, P<0.005. (D)EEG
background activity in a representative mutant
mouse (1a) recorded from left hemisphere (LH) and
right hemisphere (RH). Density spectral arrays (DSA)
corresponding to time-frequency analysis of the
same animal (1b). (2) Epileptic abnormalities (sharp
waves, arrows; spikes, asterisk) appear over
background oscillatory activity; (3) a typical
generalized cortical seizure is shown, characterized
by a low-amplitude/high-frequency onset
developing into a high-amplitude/low-frequency
activity. When the seizure ends, a marked reduction
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showed aberrant splitting of the stratum pyramidale (sPy), ectopic
localization of many NeuN-IR neurons and strong pS6 activation.
Several ring heterotopias were present throughout the stratum
lacunosum moleculare (SLM) and the hippocampal fissure.
Doublecortin (DCX)-IR neuronal progenitors in the mutant
subgranular zone (SGZ) of the DG displayed a highly extended
neurite organization, mature morphology and increased size
compared with controls (116±3 and 133±6 μm2, average area of
control versus mutant cells, Student’s t-test, P<0.0001).
To assess whether mTOR pharmacological inhibition can revert
the epileptic and megalencephalic manifestations of the mutant
phenotype, we delivered rapamycin from P8 to P40. All mutant
mice treated by this regimen stopped developing seizures and were
still alive at P40. Notably, both cortical thickness and S6
phosphorylation in rapamycin-treated mutant mice (mut ‘rapa on’)
at P40 were identical to that of vehicle-treated wild-type mice
(Fig. 3A). Because cortical neurogenesis does not take place
postnatally, rapamycin-induced cortical thickness normalization
might occur through other mechanisms, such as cortical neuropil
remodeling. Indeed, rapamycin treatment induced a severe
reduction in cortical reactive astrogliosis in the mutant cortex
(Fig.  3A) (Magri et al., 2011). Within 10 days after rapamycin
discontinuation, i.e. at P50, all mutant mice (mut ‘rapa off ’)
developed seizures and eventually died. Although pS6
hyperactivation was still seen in P50 ‘rapa off ’ mutant cortices,
cortical size did not increase back to the original mutant size, in
line with the absence of de novo astrogliosis after rapamycin
withdrawal (Fig. 3A).
Loss of Tsc1 in RGCs impairs the organization of the postnatal SVZ
niche and induces the development of postnatal SEN-like lesions
Although the analysis of SVZ neurogenesis was not reported for
Tsc2c/–/hGFAP2-Cre+ mutant mice, we set out to assess whether
mTORC1 hyperactivation in RGCs would result in SVZ alterations,
as previously reported in Tsc1c/–/Emx1-Cre+ mice (Magri et al.,
2011). At P15, the lateral ventricles of Tsc1c/–/hGFAP2-Cre+ mutant
Disease Models & Mechanisms 1189
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Fig. 2. Targeted inactivation of Tsc1 in RGCs results in postnatal
megalencephaly and cortical alterations. (A)IHC on P15 control and mutant
cortex for pS6S235/6, NeuN, Nissl, GFAP, Smi311 and pSTAT3. Increased cortical
thickness and enhanced pS6 activation are observed in the cortex of P15
mutant mice. An ectopic pS6/NeuN-IR cell layer is detected in the mutant
cortex (arrows and inset). No differences in cell size were seen throughout the
control and mutant cortex, with the exception of cells located in the ectopic
layers in the mutant cortex (Nissl staining). Most NeuN-IR neurons were also
pS6-IR. By contrast, GFAP-IR cells do not hyperactivate pS6. Smi311-IR
pyramidal neurons were profoundly disarranged in the mutant cortex (inset a
and b). pSTAT3-IR cells were seen in P15 mutant cortex (arrows in high-
magnification panel). Magnification 100×, insets 400×. (B)Quantification of
cell size in the different layers of the P15 mutant and control cortex, as
measured by unbiased automated cell area calculation, indicates enlarged cell
size in the ectopic layer localized between layer VI and the CC in mutants.
(C)Western blot on control and mutant cortex at P15. *: Tsc1 unspecific band.
Arrow: Tsc1 specific band. Tsc1, Tsc2 and PTEN expression was normalized
over β-tubulin, whereas pAKTS473, pERK, pS6S235/236, pmTORS2481, pPKCαS643
and pSTAT3S727 activation was normalized over the corresponding total
protein. Results are the average of the analysis of three samples per genotype.
Densitometric analysis, error bars, s.e.m. (D)IHC on P15 control and mutant
cortex for oligodendroglial markers such as MBP, CNPase (inset a and b) and
Olig2 (inset c and d). Reduced myelination and a low number of Olig2-IR
progenitors were detected in the mutant cortex compared with controls.
Magnification 100×, inset 400×. cc, corpus callosum. *P<0.05; ***P<0.005.
Fig. 3. Chronic rapamycin treatment
reverts cortical and SVZ
abnormalities. (A)Chronic rapamycin
treatment reduced pS6-IR cells and
megalencephaly in P40 mutant ‘rapa
on’ mice, probably through the
reduction in cortical astrogliosis
(GFAP-IR cells). Rapamycin
discontinuation from P40 to P50 led to
pS6 reactivation but did not affect the
normalization of the cortical
cytoarchitecture and the extent of
reactive gliosis in mutant brains
(mutant ‘rapa off’ mice) as compared
with controls. cc, corpus callosum.
Quantification of cortical thickness
changes is shown on the right.
***P<0.005. (B)Chronic rapamycin
treatment normalized SVZ alterations
in P40 mutant ‘rapa on’ mice to control
levels. Rapamycin discontinuation
from P40 to P50 induced pS6
reactivation without promoting the
reformation of SVZ aberrant structures
in mutant brains (mutant ‘rapa off’
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brains were abnormally enlarged (Fig.  1A; Fig. 4A). Indeed, as
opposed to controls, S100β-IR ependymal cells in the mutant brain
were all pS6-IR, suggesting that mTOR hyperactivation in these
cells might affect their functionality, thus leading to ventricular
enlargement.
Most interestingly, the same aberrantly expanded SVZ region
previously detected in postnatal Tsc1c/–/Emx1-Cre+ mice was
observed also in Tsc1c/–/hGFAP2-Cre+ mutant brain (Fig. 4B). This
expansion was reminiscent of typical TSC-associated neuroglial
SENs because it contained both DCX-IR neuroblasts, also
organized as small heterotopic clusters along the entire lateral wall
of the SVZ (Fig. 4B), and GFAP-IR astrocytes (Fig. 4C). Remarkably,
aberrant expression of the neuronal marker NeuN was seen in the
mutant SVZ, suggesting premature differentiation of mutant SVZ
dmm.biologists.org1190
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Fig. 4. Loss of Tsc1 expression in RGCs
severely impairs the organization of the
postnatal SVZ niche. (A)Enhanced
dilatation of lateral ventricles (LVs) in
mutant brains at P15. Enhanced pS6
activation (inset a and b) was seen along
the whole lateral ventricles only in mutant
brains. S100β expression (inset c and d) was
similar in both controls and mutants.
Magnification 40×, inset 100×. (B)H&E
staining depicting the increased number of
cells in the expanded SVZ in mutants (inset
a and b). Increased numbers of type A
progenitors immunoreactive for DCX in the
SVZ expansion in mutants (inset c and e).
Multilayered SVZ and DCX-IR cell clusters in
the lateral wall of the mutant ventricle
(inset d and f; coronal sections, 40×, 100×).
(C)Higher frequency of GFAP-, pS6- and
NeuN-IR cells is observed in the mutant SVZ
than in controls (200×). GFAP-IR cells are
pS6 negative. The mutant SVZ also contains
some pSTAT3-IR cells, which are restricted
to the lateral ventricle-verging side of the
ventricular wall (inset a, 1000×). The
frequency of Ki67-IR cells is decreased in
the mutant SVZ (DAPI, blue; Ki67, green).
(D)H&E, pS6, DCX, NeuN and GFAP staining
highlights major defects in the organization
of the mutant RMS at P15 (sagittal sections,
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neuroblasts, which normally differentiate into mature neurons only
after reaching their final destination, i.e. the olfactory bulbs (OBs)
(Petreanu and Alvarez-Buylla, 2002). Similar to the mutant cortex,
GFAP-IR cells in the SVZ did not activate pS6 (Fig. 4C). Notably,
pSTAT3-IR cells were seen along the dorsal wall of the SVZ in close
contact with the lateral ventricles (Fig. 4C). In agreement with the
benign nature of human SENs, the percentage of Ki67-IR cells in
the aberrant mutant SVZ expansion at P15 was lower than in
controls (32.1±0.7% and 10.3±0.7% in P15 control and mutant SVZ,
respectively; Fig. 4C).
In line with SVZ alterations, loss of Tsc1 expression in RGCs led
to defects in the organization of the rostral migratory stream (RMS).
Indeed, the mutant RMS was thickened and contained many pS6-
IR cells, multiple layers of DCX-IR cells and increased numbers of
NeuN-IR and GFAP-IR cells (Fig.  4D), compared with controls.
Accordingly, the anatomical targets of neuroblast migration along
the RMS, i.e. the OBs, were morphologically abnormal (Fig. 4D).
Again, both the ventricular enlargement and the abnormal SVZ
expansion were reverted in rapamycin-treated mutant mice, and
did not reoccur upon rapamycin suspension, in spite of pS6 re-
activation (Fig. 3B) (Magri et al., 2011).
Severe alterations in cortical development and SVZ organization
are detected at E18.5 and maintained postnatally
As opposed to Tsc2c/–/hGFAP2-Cre+ mice, increased cortical
thickness and SVZ disturbances were already observed in
Tsc1c/–/hGFAP2-Cre+ brains at E18.5 (Fig. 5A) and maintained at
P7 (not shown and Fig. 6A). Similar to P15 mutant brain, pS6
activation at E18.5 was seen throughout all the cortical layers
(Fig. 5B). The CC in the mutant brain was also highly enlarged as
compared with controls. Interestingly, NeuN staining highlighted
disorganized cortical lamination in mutants, with evident loss of
neuronal alignment in the upper cortical layers as well as increased
intercellular matrix and enlarged neuropil in the lower cortical
layers (Fig. 5B). Ectopic invasion of the prospective CC by DCX-
IR cells was specifically detected in the mutant cortex.
As opposed to Tsc1c/–/Emx1-Cre+ mice, the SVZ expanded
region in Tsc1c/–/hGFAP2-Cre+ mice at late embryonic and/or
perinatal stages did not protrude into the ventricle. On the contrary,
the Tsc1c/–/hGFAP2-Cre+ mutant SVZ consisted of thickened
multilayered cellular areas that lined the whole ventricle (Fig. 5C).
A high number of pS6-IR cells, DCX-IR neuroblasts and NeuN-IR
neurons was observed all around the mutant ventricle, whereas
increased numbers of GFAP-IR cells were found in the dorsal and
medial walls.
Activation of mTORC1 in postnatal NSCs reduces their self-
renewal, induces premature astroglial differentiation, and inhibits
neuronal and oligodendroglial cell maturation
Whereas at E18.5 the frequency of Ki67-IR cells in control and
mutant SVZ was similar (57.1±2.1% and 57.5±2.5%, respectively),
the frequency of Ki67-IR in the mutant SVZ postnatally was
Disease Models & Mechanisms 1191
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Fig. 5. Defects in the organization of the mutant cortex
and SVZ are already detected at late embryonic
developmental stages. (A)Increased cortical thickness in the
mutant brain is observed at E18.5 (coronal sections, 40× and
inset a and b, 200×). ***P<0.005. Error bars, s.e.m.
(B)Enhanced activation of pS6 in the mutant cortex at E18.5
(40× and inset a and b, 200×). Lamination defects in the
mutant cortex are highlighted by NeuN and DCX staining
(magnification 200×). DCX-IR cells massively infiltrate the
prospective CC (arrows). (C)Higher number of pS6-, DCX-,
NeuN- and GFAP-IR cells in the mutant SVZ at E18.5 (100×).
DW, dorsal wall of the ventricle; LW, lateral wall of the
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significantly lower than in controls (54.0±1.0% and 13.0±1.0% in
P7 control and mutants, respectively; Fig. 6A for P7 and Fig. 4C
for P15). Thus, a progressive decline in the proliferation of mutant
SVZ progenitors was detected throughout postnatal development.
To assess the role of mTOR pathway hyperactivation in postnatal
SVZ NSCs ex vivo, we established long-term expanding NSC lines
at P7. At this postnatal stage, both mutant cortex (data not shown)
and SVZ displayed the same alterations as detected at P15, including
enhanced pS6 activation, reduced proliferation and
hypomyelination (Fig. 6A and not shown). As opposed to dorsally
located Tsc1c/–/Emx1-Cre+ postnatal SVZ NSCs, which in vitro
were taken over by non-recombined laterally and medially located
postnatal SVZ NSCs, Tsc1c/–/hGFAP2-Cre+ postnatal SVZ NSCs
showed almost complete Cre-mediated Tsc1 loss at the genomic
level, indicating that, in these mutants, recombination was taking
place in all NSCs lining the walls of the lateral ventricles, thus
allowing the establishment of efficiently recombined postnatal NSC
lines (Fig. 6B).
Tsc1 and Tsc2 expression was significantly reduced and S6
phosphorylation highly increased in all mutant cultures (n=3
different pairs of postnatal NSC lines) (western blot, Fig.  6C).
Phosphorylation of STAT3Ser727 was higher in mutant postnatal
NSCs than in control, whereas pAKT, pERK, PTEN and pPKCα
levels did not change. Interestingly, compared with controls, a
significant decrease in long-term self-renewal and in clonal
efficiency was observed in mutant postnatal NSCs (Fig. 6D), which,
even in the presence of EGF and FGF2, acquired the appearance
of highly differentiated cells (Fig.  6E). Indeed, undifferentiated
mutant cultures, which were mostly pS6- and pSTAT3-IR,
comprised many GFAP-IR astrocyte-like cells that displayed an
aberrant morphology (Fig. 6F). In line with the role of STAT3 in
promoting GFAP expression by binding to its promoter, most
GFAP-IR cells were also pSTAT3-IR (Fig.  6F). Interestingly,
mTORC1 inhibition by rapamycin reduced pS6 activation and
reverted the premature glial differentiation in mutant postnatal
NSCs to control levels (Fig. 6F).
To assess whether the mTOR pathway might also regulate the
multilineage differentiation potential of postnatal NSCs and the
maturation of their progeny, control and mutant postnatal NSCs
were induced to differentiate and to mature for up to 8 days in vitro
(Fig. 6G). After 3 days in the presence of the sole FGF2, a condition
that drives the commitment of postnatal NSCs into
bipotent/unipotent progenitors, all mutant postnatal NSC-derived
progenitor cells activated pS6, but no difference was observed in
terms of neuronal lineage commitment as compared with controls
(not shown). By contrast, under maturation-promoting culture
conditions, mutant postnatal NSC-derived cultures, which still had
activated pS6 in most cells, were almost completely devoid of Tuj1-
IR neuronal cells but comprised a normal number of GFAP-IR
astrocytes, although the morphology of these cells was abnormal.
Most notably, in agreement with the hypomyelination detected in
the mutant CC in vivo at P15 (Fig. 2D), the number of GalC-IR
oligodendrocytes in mutant postnatal NSC-derived differentiated
cultures was strongly reduced compared with controls, a
phenomenon that was not observed in embryonic NSCs isolated
at E16.5 from Tsc1c/–/Emx1-Cre+ mice. Depletion of GalC-IR
oligodendrocytes was probably due to a defect in the maturation
of NG2-IR precursors into mature oligodendrocytes, as suggested
by the increased frequency of NG2pos/GalCneg cells in mutant
cultures (Fig. 6G).
Once more, treatment of postnatal NSC-derived progeny with
rapamycin led to normalization in the morphology of aberrant
GFAP-IR cells and decreased the number of NG2pos cells to control
levels (Fig.  6G). However, rapamycin was ineffective in rescuing
the loss in Tuj1-IR neurons and GalC-IR oligodendrocytes. Overall,
mTOR hyperactivation in postnatal neural progenitors promoted
early astroglial commitment and differentiation, followed by
dysfunctional neuronal and oligodendroglial maturation.
To understand whether the impaired oligodendroglial
differentiation observed exclusively in Tsc1c/–/hGFAP2-Cre+
postnatal NSCs was related to the stage of development at which
the NSC cultures were established (i.e. postnatal versus embryonic)
or to the progenitor cell type in which Tsc1 deletion originally took
place (i.e. RGCs versus NEPs), we established cortical embryonic
NSCs from Tsc1c/–/hGFAP2-Cre+ mice at E16.5, i.e. the same time
point at which we previously isolated embryonic NSCs from
Tsc1c/–/Emx1-Cre+ mice (supplementary material Fig. S3). When
maintained under proliferative culture conditions, Tsc1c/–/hGFAP2-
Cre+ embryonic NSC lines showed a significant decrease in long-
term self-renewal and in clonal efficiency (supplementary material
Fig. S3A), and acquired the appearance of differentiated cells
(supplementary material Fig. S3B). Most mutant embryonic NSC
lines showed complete Tsc1 loss (supplementary material Fig. S3C).
Again, mutant embryonic NSCs, which were all pS6-IR, comprised
many abnormal GFAP-IR cells and hyperactivated the STAT3
pathway (supplementary material Fig. S3D). After 3 days in FGF2,
in contrast with postnatal NSCs, mutant pS6-IR embryonic NSC-
derived progenitors gave rise to a higher number of Tuj1- and
GFAP-IR cells than did controls, confirming premature
differentiation (supplementary material Fig. S3E). Under
maturation-promoting culture conditions, mutant cultures showed
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Fig. 6. Activation of the mTOR pathway in P7 postnatal NSCs finely
regulates their self-renewal ability and their differentiation. (A)Higher
frequency of pS6- and DCX-IR cells in the aberrantly expanded mutant SVZ at
P7. A lower frequency of Ki67-IR cells was detected in mutant SVZ (200×).
(B)PCR analysis on genomic DNA from single mouse-derived control (wt) and
mutant (mut) postnatal (p)NSCs, showing full recombination of the floxable
allele. (C)Western blot on P7 control and mutant pNSCs. *: TSC1 unspecific
band. Arrow: TSC1 specific band. TSC1, TSC2 and PTEN expression was
normalized over β-tubulin, whereas pAKTS473, pERK, pS6S235/236, pmTORS2481,
pPKCαS643 and pSTAT3S727 activation were normalized over the corresponding
total protein. Results are the average of three pNSC lines per genotype.
Densitometric analysis, error bars, s.e.m. (D)Long-term growth curve and
clonal efficiency of control and mutant pNSCs, indicating reduced self-renewal
in mutant pNSCs. (E)Phase-contrast microphotographs of control and mutant
pNSCs. Magnification 200×. (F)Increased S6 phosphorylation, premature
astrocytic differentiation and pSTAT3 phosphorylation were detected in
mutant pNSCs and were reverted by rapamycin. Immunofluorescence
showing nuclear localization of pSTAT3S727 in ectopic GFAP-IR cells in
undifferentiated mutant pNSC cultures. Magnification 200×. (G)Increased S6
phosphorylation and aberrant differentiation of pNSCs into GFAP-IR astrocytes
after FBS addition was fully rescued by rapamycin treatment. Defective
oligodendrogenesis was restored by rapamycin in terms of number of NG2
oligodendrocyte progenitors, whereas impaired maturation of Tuj1-IR neurons
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a higher frequency of pS6-, pSTAT3-, Tuj1- and GFAP-IR cells,
again indicating both mTORC1-STAT3 pathway activation and
enhanced neuronal and astroglial differentiation. Most notably,
similar to embryonic NSCs from Tsc1c/–/Emx1-Cre+ mice, RGC-
targeted Tsc1 mutant embryonic NSCs comprised the same
frequency of GalC-IR oligodendrocytes as control cultures, with
only a slight increase in the numbers of NG2pos/GalCneg-IR
progenitor cells (supplementary material Fig. S3F). Thus, impaired
oligodendrogenesis is a unique feature of postnatal NSCs and does
not relate to the type of embryonic neural progenitors (NEPs vs
RGCs) targeted by mutation.
Premature astroglial differentiation and impaired neuronal
maturation of postnatal NSCs are STAT3-dependent, whereas
defective oligodendrogenesis is STAT3-independent
To assess whether the alterations in the differentiation of mutant
postnatal NSCs were also dependent on the activation of the STAT3
pathway, we exposed Tsc1 control and mutant postnatal NSCs to
the STAT3 inhibitor JSI-124 (also known as cucurbitacin) under
proliferative conditions. Exposure to the inhibitor was sufficient to
reduce the number of pSTAT3-IR cells and to restore the number
of Tuj1-, GFAP- and NG2-IR cells in mutant postnatal NSCs to
control levels (Fig. 7A), also in differentiated postnatal NSC-
derived cultures (Fig.  7B). However, the reduced generation of
GalC-IR oligodendrocytes in mutant postnatal NSC cultures was
not efficiently rescued by STAT3 inhibition, suggesting that
defective oligodendroglial maturation was STAT3-independent.
Accordingly, no evidence of STAT3 hyperactivation was found in
the CC of mutant postnatal brains compared with controls (not
shown).
Interestingly, exposure of control postnatal NSCs to JSI-124
resulted in a dramatic decrease in the frequency of Tuj1-IR neuronal
cells, suggesting that minimal activation of the STAT3 pathway is
required for proper neurogenesis to take place (supplementary
material Fig. S4).
DISCUSSION
TSC is a multisystem autosomal dominant disorder, resulting from
mutations in either the TSC1 or TSC2 gene, whose corresponding
gene products, hamartin and tuberin, respectively, form a
heterodimeric complex. Two thirds of TSC cases result from
sporadic genetic mutations in one of the two major loci identified,
i.e. TSC1 on chromosome 9q34 and TSC2 on 16p13. Loss of
hamartin-tuberin GAP activity, as occurs in TSC-associated lesions,
results in mTOR pathway hyperactivation. Because tuberin only
contains the GAP-activating domain, it is commonly believed that
mutations in TSC2 give rise to a more severe phenotype than
mutations in TSC1. However, additional pathophysiological
mechanisms might be responsible for the distinct phenotypic
features observed in individuals bearing mutations in either TSC1
or TSC2. In fact, whereas truncating mutations in TSC2 induce
mRNA degradation and, in few cases, short non-functional
proteins, non-truncating TSC2 mutations, such as missense and
small in-frame mutations, produce distinct and, in most cases,
milder phenotypes than truncating mutations (van Eeghen et al.,
2012; van Eeghen et al., 2013). In agreement with the high variability
in phenotype, mutations in the tuberin interacting domain (TID)
of TSC1 are associated with highly severe neurocognitive
impairment, whereas distal mutations in the TSC2 protein, which
do not affect the hamartin interacting domain (HID), result in
significantly better outcomes (van Eeghen et al., 2012). As such,
given the quite consistent overlap in phenotypes in individuals
dmm.biologists.org1194
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Fig. 7. Premature astroglial differentiation and impaired neuronal
maturation of postnatal NSCs are STAT3-dependent, whereas defective
oligodendrogenesis is STAT3-independent. (A)Increased frequency of Tuj1-
IR neurons and decreased numbers of GFAP-IR astrocytes in undifferentiated
mutant postnatal NSC (pNSC) cultures after 72 hours of exposure to the STAT3
inhibitor JSI-124. The number of NG2/GalC-IR oligodendrocytes is not affected
by treatment with JSI-124. pS6 and pSTAT3 status after JSI-124 treatment is
also shown. Magnification 200×. (B)Increased frequency of Tuj1-IR neurons
and decreased numbers of GFAP-IR astrocytes in mutant pNSC cultures
induced to differentiate and mature by FBS addition after 72 hours of
exposure to JSI-124. Again, the number of NG2/GalC-IR oligodendrocytes is
not affected by treatment with JSI-124. pS6 and pSTAT3 status after JSI-124
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bearing either TSC1 or TSC2 mutations (Jansen et al., 2008),
phenotype prediction is complicated and should be based more on
the type of mutations rather than on the gene in which the
mutation actually takes place (van Eeghen et al., 2012).
Recently, conditional mouse models for TSC have been generated
by targeting Tsc1 or Tsc2 mutations in differentiated neural cells
(Meikle et al., 2007; Ehninger et al., 2008; Uhlmann et al., 2002a;
Zeng et al., 2011). However, none of these mouse models fully
recapitulated the pathological features of the disease (Crino et al.,
2006), probably as a consequence of the advanced stage of
differentiation of the cells targeted by the recombination event,
rather than being due to the mutation event per se. As such, others
and we recently generated novel mouse models of TSC by deleting
Tsc1 or Tsc2 earlier in undifferentiated embryonic progenitors (Way
et al., 2009; Magri et al., 2011; Carson et al., 2012; Feliciano et al.,
2011) and postnatal SVZ NSCs (Zhou et al., 2011; Feliciano et al.,
2012). Notably, these conditional mouse models displayed most of
the distinctive neurological features of TSC.
Besides being invaluable for their preclinical exploitability,
mouse models of TSC can also be highly informative in the
identification of a possible association between genotype and
phenotype in TSC. A previous study exploiting astrocyte-specific
(hGFAP1-Cre) Tsc1 and Tsc2 knockout models reported that,
although the two models were qualitatively similar in the
neurological phenotype in terms of spontaneous epilepsy,
progressive glial proliferation, impaired glial buffering
mechanisms and hippocampal neuronal disorganization, seizures
and some histological features were more severe in Tsc2 than in
Tsc1 mutant mice and this was due to the distinct degree of mTOR
pathway activation in the two models (Zeng et al., 2011). By
contrast, in the current study, we show that the radial-glia-specific
(hGFAP2-Cre) Tsc1 knockout mouse, in which mTOR
hyperactivation was achieved through a remarkable decrease not
only in hamartin but also in tuberin expression, displayed
overlapping phenotypic features with the corresponding Tsc2
knockout model (Way et al., 2009). Indeed, both mouse models,
which shared the same mixed genetic background, were
characterized by short lifespan, reduced weight gain, severe
megalencephaly and ventricular enlargement, increased cortical
thickness, cortical lamination defects, hippocampal alterations,
hypomyelination, and spontaneous epilepsy. Notably, similar to
the developmental defect detected in the SVZ of the NEP-specific
Tsc1 knockout model (Magri et al., 2011), an aberrant SVZ
expansion was observed in RGC-specific Tsc1 mutant mice that
seemed to be present also in RGC-specific Tsc2 mutant mice, in
which it was interpreted as astrogliosis (Way et al., 2009).
Overall, the differences in the neuroanatomical and cellular
pathophenotypes induced by Tsc1 or Tsc2 mutation in CNS-
restricted mouse models, which, however, do not take into account
potential differences in behavior and cognition, seem to mostly
relate to the type of cell targeted by the loss of hamartin and tuberin,
i.e. embryonic undifferentiated progenitors versus differentiated
cells, rather than to mutation in Tsc1 or Tsc2. Anyhow, given that
Tsc2 deletion in astrocytes required more than 5 weeks to induce
more severe neurological disturbances than the corresponding Tsc1
mutation (Zeng et al., 2011), we cannot rule out that the short
lifespan of both RGC-targeted mutant mice might prevent the
manifestation of time-dependent differences in Tsc1- and Tsc2-
deletion-associated phenotypes. Inducible conditional transgenesis
could be exploited to solve this issue.
Notwithstanding the many similarities detected in the two RGC-
targeted models, several features remained strikingly different. As
reported also in the NEP-targeted model, Tsc1c/–/hGFAP2-Cre+
mutant cortices did show differences in cell size only in the ectopic
cortical layer detected between layer 5 and 6. Likewise, none of the
many GFAP-IR cells found in the Tsc1c/–/hGFAP2-Cre+ mutant
cortex overactivated mTOR. In addition, a significant increase in
cortical thickness was observed in Tsc1c/–/hGFAP2-Cre+ mice as
early as at E18.5, whereas, in the Tsc2/hGFAP2-Cre+ mutants, it
was detected only by P10. As such, although resulting in grossly
similar phenotypes, Tsc1 mutation in RGCs leads to the
development of gene-specific alterations.
Remarkably, the pivotal role of the timing of mutations in
determining the severity of phenotype in TSC mouse models is
supported by observations in mTOR-hyperactivating embryonic
and postnatal NSCs. With respect to the NEP-targeted mouse
model in which Tsc1 loss postnatally was restricted to the
dorsolateral corner of the SVZ, the Tsc1c/–/hGFAP2-Cre+ mutant
mouse carries the relevant advantage of deleting Tsc1 in the whole
SVZ region, thus allowing the establishment of long-term
expanding postnatal mutant NSC lines. In fact, studying the
function of mTOR not only in the regulation of embryonic NSCs
but also in postnatal NSCs is of great biological and preclinical
relevance because it has been recently reported that this pathway
regulates both quiescence and proliferation of SVZ progenitor pools
at different stages throughout adulthood (Paliouras et al., 2012).
Indeed, Tsc1c/–/hGFAP2-Cre+ postnatal NSCs showed an aberrant
differentiation potential that was very different from the one of
E16.5 Tsc1c/–/hGFAP2-Cre+ embryonic NSCs.
By keeping in mind that in vitro culturing does not fully mimic
the in vivo microenvironment conditions, it is interesting to note
that the aberrant differentiation detected in mutant postnatal NSCs
can be rescued differently by mTOR and STAT3 inhibition. The
defect in the differentiation of GFAP-IR astroglial cells and NG2-
IR oligodendroglial progenitors was reverted by both rapamycin
and JSI-124. By contrast, the decrease in GalC-IR cells in vitro was
both rapamycin-insensitive and STAT3-independent. Remarkably,
the impaired neuronal differentiation of postnatal NSCs was
rapamycin-insensitive but STAT3-dependent. As such, it is
tempting to speculate that different inhibitory approaches might
be exploited in vivo, alone or in combination, in order to interfere
with the distinct phenotypic features associated with TSC.
Interestingly, E16.5 mutant embryonic NSCs isolated from RGC-
recombined Tsc1c/–/hGFAP2-Cre+ mice showed an enhanced
neurogenic potential that, conversely, was lost in E16.5 mutant
embryonic NSCs isolated from NEP-recombined Tsc1c/–/Emx1-
Cre+ mice as well as in P7 postnatal NSCs isolated from RGC-
recombined Tsc1c/–/hGFAP2-Cre+ mice. The difference in
neurogenic potential might be ascribed to the time that targeted
NSCs spent in the presence of strong mTORC1 hyperactivation in
vivo. In the case of Tsc1c/–/Emx1-Cre+ mice, in which Cre-mediated
recombination took place at E9.5, E16.5 embryonic NSCs spent 5-
7 days under mTOR hyperactivation. Similarly, P7 postnatal NSCs
from Tsc1c/–/hGFAP2-Cre+ mice, in which Cre was activated at
E13.5, were exposed to mTOR hyperactivation for 10-12 days. By
contrast, E16.5 embryonic NSCs from RGC-recombined
Disease Models & Mechanisms 1195















    
   D
M
M
Tsc1c/–/hGFAP2-Cre+ mice were under the activity of
hyperstimulated mTOR for only 1-3 days. In further support of
this notion, P7 postnatal NSC cultures isolated from the
Tsc1c/c/Nestin-CreERT2+ mouse and Cre-recombined ex vivo at the
same postnatal day, and, as such, not experiencing mTOR
hyperactivation in vivo, did not display any alteration in their
differentiation potential (Zhou et al., 2011). Thus, sustained
activation of mTOR leads to defects in neurogenesis that are also
dependent on the length of the period during which hyperactivation
of mTORC1 occurs.
Overall, these findings indicate that mTOR activation in neural
progenitors plays distinct roles depending on the developmental
stage at which it takes place, and that genotype-phenotype
correlation, at least in preclinical mouse models, might depend on
the nature of the cells targeted by the mutation.
MATERIALS AND METHODS
Generation of Tsc1-floxed/hGFAP2Cre mice
To generate Tsc1c/chGFAP2Cre conditional mice, mixed
background (129S4/SvJae, C57BL/6) Tsc1c/c mice (Jackson) of
either sex were intercrossed with male or female hGFAP2Cre
heterozygous mice (Zhuo et al., 2001). We used ‘c’, ‘wt’ and ‘–’  to
denote the conditional (floxed), wild type and null alleles of Tsc1,
respectively; the formal name of the c allele is Tsc1tm1Djk. Tsc1
mutants were genotyped by tail-derived genomic DNA PCR as
described previously (Uhlmann et al., 2002b). All animal
experiments were approved by and performed in accordance with
the guidelines of the Institutional Animal Care and Use Committee.
Immunostaining on paraffin-embedded and frozen sections
Brains from embryos or from intracardially perfused postnatal mice
were fixed for 24 hours in 4% PFA. 2-μm paraffin and 16-μm frozen
sections underwent endogenous peroxidase activity blocking by
0.3% H2O2 in methanol, were then treated for antigen retrieval and
incubated with primary antibodies at room temperature (RT) for
1 hour. Primary antibodies used were: rabbit anti-pS6S235/6 (Cell
Signaling), rabbit anti-Ki67 (Novocastra), rat anti-Ki67 (TEC3,
Dako), mouse anti-NeuN (Chemicon), mouse anti-SMI311
(Covance), rabbit anti-pSTAT3Y705 and -pSTAT3S727 (Cell
Signaling), goat anti-DCX (Santa Cruz Biotechnology), mouse anti-
GFAP (Chemicon), rabbit anti-GFAP (Dako), rabbit anti-Iba-1
(Wako), mouse anti-MBP (Millipore), mouse anti-CNPase
(Chemicon), rabbit anti-Olig2 (Millipore) and rabbit anti-S100β
(Swant).
Immunoblotting
Western blotting on cortical tissues and postnatal NSC cultures
was performed as described previously (Magri et al., 2011). The
primary antibodies/antisera used were: rabbit anti-pS6S235/6, anti-
S6, anti-Tsc1 (code 4906, Cell Signaling), anti-Tsc2, anti-mTOR,
anti-pmTORS2481, anti-Akt, anti-pAktS473, anti-ERK, anti-pERK,
anti-PKCα, anti-PTEN, anti-STAT3 and anti-pSTAT3S727 (all
antibodies from Cell Signaling), rabbit anti-pPKCαS643 (Millipore)
and anti β-tubulin (Sigma). Reactive proteins were visualized using
LiteBlot (Euroclone, Celbio) or SuperSignal West Femto
chemiluminescence reagent (Pierce Biotechnology) by exposure to
X-ray film (BioMax MR; Kodak).
Video-EEG recording
Epidural stainless steel screw electrodes (0.9 mm diameter/2 mm
long) were surgically implanted at P11 under sevoflurane anesthesia
(Sevorane™, Abbott S.p.a. Campoverde, Italy) and secured using
cyanoancrylate and dental cement (Ketac Cem, ESPE Dental AG,
Seefeld, Germany). Two active electrodes were placed on right and
left parietal areas (2 mm lateral to midline, 1 mm posterior to
bregma) and one over the occipital area (1 mm posterior to
lambda) as a common reference. After 24-hour recovery,
unrestrained mice were monitored by video-EEG in recording
sessions of 12-24 hours in a Faraday cage. EEG data were recorded
and digitally saved using a System Plus device (Micromed, Mogliano
Veneto, Italy). Tracings were filtered between 0.53 and 60 Hz.
Simultaneous video data were acquired with a Canon MV550I
camera connected to the recording system via Firewire. Video-EEG
recordings were visually inspected off-line for detection of
spontaneous seizures. Time-frequency analysis was performed
offline and results were represented by density spectral arrays
(DSAs).
Isolation and culturing of NSCs
NSC cultures were established under mild hypoxic (5% O2) culture
conditions from the embryonic cerebral cortex and the postnatal
SVZ of wild-type and mutant mice. NSC long-term self-renewal
was assessed as in Magri et al. (Magri et al., 2011). For clonogenic
assays, cells derived from the dissociation of clonal single
neurospheres were seeded in 96-well plates and the number of
secondary spheres generated was assessed after 8-10 days. To
evaluate multipotency, NSCs were plated onto Matrigel-coated
glass coverslips in the presence of FGF2 for 3 days, and then
switched to medium containing 2% FBS for an additional 4 days.
Cells were fixed with 4% PFA for 20 minutes and then processed
for the detection of neural antigens. Primary antibodies used were:
mouse anti-GFAP (Chemicon), rabbit anti-GFAP (Dako), mouse
anti-Tuj1 (Covance), rabbit anti-pS6S235/6 (Cell Signaling), rabbit
anti-pSTAT3S727 (Cell Signaling), mouse anti-GalC (Millipore) and
rabbit anti-NG2 (Chemicon). ToPro3 (TP3) was used for nuclear
staining. The number of cells positive for each staining was
normalized over the total cell number obtained by counting TP3-
positive nuclei and expressed as a percentage. At least 1500 nuclei
were counted for each experimental condition. Mutant postnatal
NSCs were exposed to rapamycin (LC-Labs, USA) and
cucurbitacin-I hydrate (JSI-124, SIGMA) at a final concentration
of 100 nM.
Treatment with rapamycin
Mice were intraperitoneally injected with 6 mg/kg of rapamycin
or vehicle (5% Tween 80, 5% PEG 400) every other day.
Statistical analysis
Results for continuous variables were expressed as mean ± standard
error mean. Two-group comparisons were performed by the
independent samples Student’s t-test. Multiple group comparisons
were performed by the ANOVA test followed by Bonferroni post-
hoc analysis. P-values <0.05 were considered statistically significant.
*P<0.05; **P<0.01; ***P<0.005; ****P<0.001.
COMPETING INTERESTS
The authors declare that they do not have any competing or financial interests.
dmm.biologists.org1196















    




L.M. performed most experiments, analyzed the data, wrote parts of the
manuscript and edited the manuscript. M. Cominelli performed IHC experiments
and analyzed the data. M. Cambiaghi and M. Cursi performed EEG experiments,
analyzed the data and wrote part of the manuscript. L.L., F.M. and P.L.P. analyzed
the data and edited the manuscript. R.G. conceived the study, designed the
experiments and wrote the manuscript.
FUNDING
This work was supported by Associazione Sclerosi Tuberosa (AST) to R.G.
SUPPLEMENTARY MATERIAL
Supplementary material for this article is available at
http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.012096/-/DC1
REFERENCES
Benvenuto, G., Li, S., Brown, S. J., Braverman, R., Vass, W. C., Cheadle, J. P., Halley,
D. J., Sampson, J. R., Wienecke, R. and DeClue, J. E. (2000). The tuberous sclerosis-
1 (TSC1) gene product hamartin suppresses cell growth and augments the
expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene
19, 6306-6316.
Carson, R. P., Van Nielen, D. L., Winzenburger, P. A. and Ess, K. C. (2012). Neuronal
and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin.
Neurobiol. Dis. 45, 369-380.
Crino, P. B., Nathanson, K. L. and Henske, E. P. (2006). The tuberous sclerosis
complex. N. Engl. J. Med. 355, 1345-1356.
Dabora, S. L., Jozwiak, S., Franz, D. N., Roberts, P. S., Nieto, A., Chung, J., Choy, Y.
S., Reeve, M. P., Thiele, E., Egelhoff, J. C. et al. (2001). Mutational analysis in a
cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2,
compared with TSC1, disease in multiple organs. Am. J. Hum. Genet. 68, 64-80.
Devlin, L. A., Shepherd, C. H., Crawford, H. and Morrison, P. J. (2006). Tuberous
sclerosis complex: clinical features, diagnosis, and prevalence within Northern
Ireland. Dev. Med. Child Neurol. 48, 495-499.
Ehninger, D., Han, S., Shilyansky, C., Zhou, Y., Li, W., Kwiatkowski, D. J., Ramesh, V.
and Silva, A. J. (2008). Reversal of learning deficits in a Tsc2+/- mouse model of
tuberous sclerosis. Nat. Med. 14, 843-848.
Feliciano, D. M., Su, T., Lopez, J., Platel, J. C. and Bordey, A. (2011). Single-cell Tsc1
knockout during corticogenesis generates tuber-like lesions and reduces seizure
threshold in mice. J. Clin. Invest. 121, 1596-1607.
Feliciano, D. M., Quon, J. L., Su, T., Taylor, M. M. and Bordey, A. (2012). Postnatal
neurogenesis generates heterotopias, olfactory micronodules and cortical infiltration
following single-cell Tsc1 deletion. Hum. Mol. Genet. 21, 799-810.
Jansen, F. E., Braams, O., Vincken, K. L., Algra, A., Anbeek, P., Jennekens-Schinkel,
A., Halley, D., Zonnenberg, B. A., van den Ouweland, A., van Huffelen, A. C. et
al. (2008). Overlapping neurologic and cognitive phenotypes in patients with TSC1
or TSC2 mutations. Neurology 70, 908-915.
Magri, L., Cambiaghi, M., Cominelli, M., Alfaro-Cervello, C., Cursi, M., Pala, M.,
Bulfone, A., Garcìa-Verdugo, J. M., Leocani, L., Minicucci, F. et al. (2011).
Sustained activation of mTOR pathway in embryonic neural stem cells leads to
development of tuberous sclerosis complex-associated lesions. Cell Stem Cell 9, 447-
462.
Meikle, L., Talos, D. M., Onda, H., Pollizzi, K., Rotenberg, A., Sahin, M., Jensen, F. E.
and Kwiatkowski, D. J. (2007). A mouse model of tuberous sclerosis: neuronal loss
of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity,
and limited survival. J. Neurosci. 27, 5546-5558.
Michelozzi, C., Di Leo, G., Galli, F., Silva Barbosa, F., Labriola, F., Sardanelli, F. and
Cornalba, G. (2013). Subependymal nodules and giant cell tumours in tuberous
sclerosis complex patients: prevalence on MRI in relation to gene mutation. Childs
Nerv. Syst. 29, 249-254.
Paliouras, G. N., Hamilton, L. K., Aumont, A., Joppé, S. E., Barnabé-Heider, F. and
Fernandes, K. J. (2012). Mammalian target of rapamycin signaling is a key regulator
of the transit-amplifying progenitor pool in the adult and aging forebrain. J.
Neurosci. 32, 15012-15026.
Petreanu, L. and Alvarez-Buylla, A. (2002). Maturation and death of adult-born
olfactory bulb granule neurons: role of olfaction. J. Neurosci. 22, 6106-6113.
Rok, P., Kasprzyk-Obara, J., Domańska-Pakieła, D. and Jóźwiak, S. (2005). Clinical
symptoms of tuberous sclerosis complex in patients with an identical TSC2
mutation. Med. Sci. Monit. 11, CR230-CR234.
Uhlmann, E. J., Apicelli, A. J., Baldwin, R. L., Burke, S. P., Bajenaru, M. L., Onda, H.,
Kwiatkowski, D. and Gutmann, D. H. (2002a). Heterozygosity for the tuberous
sclerosis complex (TSC) gene products results in increased astrocyte numbers and
decreased p27-Kip1 expression in TSC2+/- cells. Oncogene 21, 4050-4059.
Uhlmann, E. J., Wong, M., Baldwin, R. L., Bajenaru, M. L., Onda, H., Kwiatkowski,
D. J., Yamada, K. and Gutmann, D. H. (2002b). Astrocyte-specific TSC1 conditional
knockout mice exhibit abnormal neuronal organization and seizures. Ann. Neurol. 52,
285-296.
van Eeghen, A. M., Black, M. E., Pulsifer, M. B., Kwiatkowski, D. J. and Thiele, E. A.
(2012). Genotype and cognitive phenotype of patients with tuberous sclerosis
complex. Eur. J. Hum. Genet. 20, 510-515.
van Eeghen, A. M., Nellist, M., van Eeghen, E. E. and Thiele, E. A. (2013). Central
TSC2 missense mutations are associated with a reduced risk of infantile spasms.
Epilepsy Res. 103, 83-87.
Way, S. W., McKenna, J., 3rd, Mietzsch, U., Reith, R. M., Wu, H. C. and Gambello, M.
J. (2009). Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis
complex in the mouse. Hum. Mol. Genet. 18, 1252-1265.
Zeng, L. H., Rensing, N. R., Zhang, B., Gutmann, D. H., Gambello, M. J. and Wong,
M. (2011). Tsc2 gene inactivation causes a more severe epilepsy phenotype than
Tsc1 inactivation in a mouse model of tuberous sclerosis complex. Hum. Mol. Genet.
20, 445-454.
Zhou, J., Shrikhande, G., Xu, J., McKay, R. M., Burns, D. K., Johnson, J. E. and
Parada, L. F. (2011). Tsc1 mutant neural stem/progenitor cells exhibit migration
deficits and give rise to subependymal lesions in the lateral ventricle. Genes Dev. 25,
1595-1600.
Zhuo, L., Theis, M., Alvarez-Maya, I., Brenner, M., Willecke, K. and Messing, A.
(2001). hGFAP-cre transgenic mice for manipulation of glial and neuronal function in
vivo. Genesis 31, 85-94.
Disease Models & Mechanisms 1197















    
   D
M
M
